Samsung Biologics Co Ltd (207940) — Cash Flow Reinvestment Rate
Samsung Biologics Co Ltd (207940) has a Cash Flow Reinvestment Rate of 0.35x as of September 2025, reinvesting ₩213.82 Billion (capex ₩113.81 Billion plus investments ₩-100.00 Billion) from operating cash flow of ₩619.30 Billion. Check 207940 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Samsung Biologics Co Ltd Cash Flow Reinvestment Rate (2017–2024)
Historical reinvestment intensity for Samsung Biologics Co Ltd across 7 annual periods. Explore investment intensity of Samsung Biologics Co Ltd to see how much of total assets are deployed in long-term investments.
Annual Cash Flow Reinvestment Rate for Samsung Biologics Co Ltd (2017–2024)
Year-by-year capital reinvestment analysis for Samsung Biologics Co Ltd. For live market cap and broader valuation context, see 207940 market cap overview.
| Year | Reinvestment Rate | Total Reinvested (KRW) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 1.28x | ₩2.12 Trillion | ₩1.66 Trillion | ₩1.38 Trillion | ▼ -20.2% |
| 2023 | 1.60x | ₩2.67 Trillion | ₩1.67 Trillion | ₩1.11 Trillion | ▼ -22.5% |
| 2022 | 2.07x | ₩1.97 Trillion | ₩953.05 Billion | ₩956.84 Billion | ▲ +2.4% |
| 2021 | 2.02x | ₩918.63 Billion | ₩454.60 Billion | ₩406.25 Billion | ▼ -0.4% |
| 2020 | 2.03x | ₩409.83 Billion | ₩202.09 Billion | ₩139.66 Billion | ▼ -97.2% |
| 2019 | 72.36x | ₩734.74 Billion | ₩10.15 Billion | ₩192.84 Billion | ▲ +757.6% |
| 2017 | 8.44x | ₩1.26 Trillion | ₩149.82 Billion | ₩494.12 Billion | — |